Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the publication of its 2024 Environmental, Social and Governance Report, which provides corporate sustainability disclosures for the period Jan. 1, 2023 to Dec. 31, 2023.
- – Report Highlights Company’s Focus on Red Blood Cell Health; Diversity, Equity & Inclusion; and Strong Corporate Governance –
CAMBRIDGE, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced the publication of its 2024 Environmental, Social and Governance Report, which provides corporate sustainability disclosures for the period Jan. 1, 2023 to Dec. 31, 2023. - Our ESG report is a shining reflection of our ‘how’ and a testament to the important contributions made by every function at Agios,” said Brian Goff, chief executive officer of Agios.
- Diversity at Agios: Representative, cognitive and experiential differences among team members are highly valued at Agios, and the company demonstrated tangible successes in 2023.
- To learn more about ESG at Agios, read the full report here .